Status:
COMPLETED
Patient-Centred Care for Warfarin Management: A Pilot Study to Transition Care to High Risk Patients
Lead Sponsor:
University of Alberta
Conditions:
Quality of Life
Eligibility:
All Genders
17+ years
Phase:
NA
Brief Summary
Warfarin remains the only oral anticoagulant effective in preventing stroke and valve thrombi for patients having mechanical heart valves (MHVs). Within Edmonton, Alberta, our pharmacist-directed and ...
Detailed Description
50 patients will receive a cover letter outlining their random selection for this study, along with the patient information sheet and consent form (with a return addressed, postage paid envelope). Pat...
Eligibility Criteria
Inclusion
- mechanical heart valve as the indication for warfarin
- \> 16 years of age
- Warfarin therapy managed by the AC for at least the preceding 6 months
- Anticipated duration of warfarin therapy to be lifelong
- Previously adherent with medication
- Competence judged by demonstrated ability to use drug-adjustment nomograms
Exclusion
- • Severe psychiatric disease
- Significant language barrier
- Clinician's judgment that the patient would be a poor candidate for study (with reason specified)
- Known or anticipated procedure/surgery/intervention in the next year
- Active participation in another study
- Lack of access to the internet / email
Key Trial Info
Start Date :
September 17 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2022
Estimated Enrollment :
58 Patients enrolled
Trial Details
Trial ID
NCT03295799
Start Date
September 17 2017
End Date
January 31 2022
Last Update
May 27 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alberta
Edmonton, Alberta, Canada, T6G 2J3